Jefferies has maintained a ‘Hold’ rating on Global Health Limited (Medanta), with a target price of ₹1,170. The hospital chain is actively ramping up bed additions in Lucknow and Patna, while facing delays in Indore and South Delhi. The company has outlined a ₹2,800 crore capital expenditure plan over the next five years, aiming to bolster its network and improve patient services. While progress in key regions remains positive, delays in Indore have prompted Medanta to explore alternative entry strategies for the market.
In recent developments, Global Health’s stock has shown significant performance, with shares more than doubling in the past year and reaching 52-week highs. Analysts attribute this growth to the scale-up in new and existing hospitals, ongoing expansions, and better operating leverage.
Additionally, Global Health has announced plans to establish a new 750-bed super-speciality hospital in New Delhi, aiming to enhance its service offerings and cater to a larger patient base.
These initiatives reflect Medanta’s commitment to expanding its healthcare services across India. However, the company continues to face challenges in execution, particularly with project delays in certain regions. Investors will be closely monitoring how Medanta navigates these challenges while pursuing its growth objectives.
